Physician profile
Michael Y Chew
NPI 1093788572
$10,182.07
in general payments reported to CMS, 2019-2025
20 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,007 · 2020: $722 · 2021: $891 · 2022: $1,092 · 2023: $1,324 · 2024: $1,810 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,627 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $667 · Entertainment: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,626.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $666.66 |
| Entertainment | $177.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,386.88 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Alcon Vision LLC | $2,324.01 | 2019-2025 | Tryptyr, Dailies Total1, Eysuvis |
| Bausch & Lomb Americas INC. | $2,283.46 | 2022-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $769.44 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $620.98 | 2019-2021 | |
| Oyster Point Pharma, INC. | $612.91 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $325.95 | 2021-2022 | |
| Optos, INC. | $177.33 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Genentech USA, INC. | $136.10 | 2021 | |
| Dompe US, INC. | $79.02 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $75.43 | 2022-2024 | Tearcare System |
| Optovue, INC. | $72.79 | 2019 | |
| Sun Pharmaceutical Industries INC. | $66.78 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $63.14 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $61.15 | 2024-2025 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $34.95 | 2019-2023 | Contact Lens, Spectacle Lenses |
| Johnson & Johnson Surgical Vision, INC. | $25.46 | 2021 | |
| Harrow Eye, LLC | $24.02 | 2025 | Vevye |
| Abbvie INC. | $22.87 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.